欧米茄-3脂肪酸治疗对心房风险的影响:对34项试验的更新元分析,包括114,326名个人
Nada R Abuknesha1, James H O'Keefe1,2, Frank Qian3
1Fatty Acid Research Institute, Sioux Falls, SD, USA.
medRxiv : the preprint server for health sciences
|December 25, 2025
概括
欧米茄-3脂肪酸 (EPA/DHA) 可能会增加心房动 (AF) 的风险,特别是在高风险的心血管疾病患者服用高剂量的情况下. 在治疗决策中,平衡这些风险与益处至关重要.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 最近的分析表明,欧米茄-3脂肪酸可能会增加心房动 (AF) 的风险.
- 以前的元分析受限于少数包含的随机对照试验 (RCT).
研究的目的:
- 进行关于omega-3脂肪酸和AF发病率的RCT的综合元分析.
- 研究omega-3剂量和心血管疾病 (CVD) 风险对AF发生的协同影响.
主要方法:
- 包括RCT,每天≥500毫克的多可萨赫萨酸 (DHA) 和/或eicosapentaenoic酸 (EPA) 超过12个月.
- 专注于50岁以上的参与者,最好没有先前存在的AF/心房.
- 分析了新发性AF作为主要结果,按EPA/DHA剂量和心血管疾病风险分层.
主要成果:
- 分析了34个RCT (n=114,326个).
- 显著的AF风险增加 (OR 1.48) 仅在接受高剂量的EPA/DHA (>1500 mg/天) 的高心血管疾病风险患者中观察到.
- 在其他组 (高风险/低剂量,低风险/低剂量,低风险/高剂量) 中没有发现显著的AF风险增加.
结论:
- EPA/DHA治疗增加了AF风险,主要是在使用高剂量的高心血管疾病风险人群中.
- 临床决策需要平衡潜在的AF风险与EPA/DHA治疗的已知好处.
相关概念视频
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Rheumatic Heart Disease III: Medical Management
263
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
263
Acute Coronary Syndrome III: Diagnostic Studies
194
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
194
Coronary Artery Disease IV: Preventive Measures
564
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
564
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
376
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
376
Aortic Regurgitation III: Medical Management
366
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
366


